Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger… - European Journal of …, 2024 - Wiley Online Library
Background Hydroxyurea (HU) is a commonly used first‐line treatment in patients with
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
[PDF][PDF] Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger, V De Stefano, V Accurso… - 2023 - researchgate.net
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger, V De Stefano… - European Journal of …, 2023 - zora.uzh.ch
BACKGROUND: Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger… - European journal …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger… - European Journal Of …, 2024 - lirias.kuleuven.be
BACKGROUND: Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
A Theocharides, H Gisslinger, V De Stefano… - European Journal of …, 2023 - europepmc.org
Background Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
polycythemia vera (PV). However, approximately 15%-24% of PV patients report intolerance …
[PDF][PDF] Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger, V De Stefano, V Accurso… - 2023 - pure.eur.nl
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
[PDF][PDF] Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study
A Theocharides, H Gisslinger, V De Stefano, V Accurso… - 2023 - pure.eur.nl
Background: Hydroxyurea (HU) is a commonly used first-line treatment in patients with
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …
polycythemia vera (PV). However, approximately 15%–24% of PV patients report …